Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

221 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Perspective: Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies.
Mughal TI, Pemmaraju N, Bejar R, Gale RP, Bose P, Kiladjian JJ, Prchal J, Royston D, Pollyea D, Valent P, Brümmendorf TH, Skorski T, Patnaik M, Santini V, Fenaux P, Kucine N, Verstovsek S, Mesa R, Barbui T, Saglio G, Van Etten RA. Mughal TI, et al. Among authors: royston d. Hematol Oncol. 2022 Oct;40(4):491-504. doi: 10.1002/hon.2987. Epub 2022 Apr 15. Hematol Oncol. 2022. PMID: 35368098 Review.
A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL.
Eyre TA, Hildyard C, Hamblin A, Ali AS, Houlton A, Hopkins L, Royston D, Linton KM, Pettitt A, Rule S, Cwynarski K, Barrington SF, Warbey V, Wrench D, Barrans S, Hirst CS, Panchal A, Roudier MP, Harrington EA, Davies A, Collins GP. Eyre TA, et al. Among authors: royston d. Hematol Oncol. 2019 Oct;37(4):352-359. doi: 10.1002/hon.2662. Epub 2019 Sep 9. Hematol Oncol. 2019. PMID: 31385336 Clinical Trial.
A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphoma.
Booth SW, Eyre TA, Whittaker J, Campo L, Wang LM, Soilleux E, Royston D, Rees G, Kesavan M, Hildyard C, Kazmi F, La Thangue N, Kerr D, Middleton MR, Collins GP. Booth SW, et al. Among authors: royston d. BMC Cancer. 2021 Jul 23;21(1):851. doi: 10.1186/s12885-021-08595-w. BMC Cancer. 2021. PMID: 34301221 Free PMC article. Clinical Trial.
Single-Cell Analyses Reveal Megakaryocyte-Biased Hematopoiesis in Myelofibrosis and Identify Mutant Clone-Specific Targets.
Psaila B, Wang G, Rodriguez-Meira A, Li R, Heuston EF, Murphy L, Yee D, Hitchcock IS, Sousos N, O'Sullivan J, Anderson S, Senis YA, Weinberg OK, Calicchio ML; NIH Intramural Sequencing Center; Iskander D, Royston D, Milojkovic D, Roberts I, Bodine DM, Thongjuea S, Mead AJ. Psaila B, et al. Among authors: royston d. Mol Cell. 2020 May 7;78(3):477-492.e8. doi: 10.1016/j.molcel.2020.04.008. Mol Cell. 2020. PMID: 32386542 Free PMC article.
In utero origin of myelofibrosis presenting in adult monozygotic twins.
Sousos N, Ní Leathlobhair M, Simoglou Karali C, Louka E, Bienz N, Royston D, Clark SA, Hamblin A, Howard K, Mathews V, George B, Roy A, Psaila B, Wedge DC, Mead AJ. Sousos N, et al. Among authors: royston d. Nat Med. 2022 Jun;28(6):1207-1211. doi: 10.1038/s41591-022-01793-4. Epub 2022 May 30. Nat Med. 2022. PMID: 35637336 Free PMC article.
The management of Castleman disease.
Lomas OC, Streetly M, Pratt G, Cavet J, Royston D, Schey S, Ramasamy K; British Society for Haematology (BSH) Committee. Lomas OC, et al. Among authors: royston d. Br J Haematol. 2021 Nov;195(3):328-337. doi: 10.1111/bjh.17688. Epub 2021 Aug 2. Br J Haematol. 2021. PMID: 34340261 No abstract available.
221 results